Short answer
Medicare Part D covers Ozempic for type 2 diabetes.
The Congressional Research Service says Ozempic (semaglutide) is approved for type 2 diabetes, which is a medically accepted indication, so Medicare Part D covers it for that use. It says GLP-1 drugs are not covered under Part D when used for weight loss. Ozempic is not part of the new GLP-1 Bridge, which covers certain weight-management drugs. CMS says Ozempic was selected for Medicare drug price negotiation, with negotiated prices effective in 2027.
Start here
What you actually came to find out
Plain answers first. Sources stay below for checking details.
Is Ozempic covered?
The CRS says Part D covers it for type 2 diabetes.
For weight loss?
The CRS says Part D excludes GLP-1 drugs used only for weight loss.
Is it in the Bridge?
No. The Bridge covers certain weight-management drugs, not Ozempic.
Will the price change?
CMS says Ozempic was selected for negotiation, effective 2027.
Diabetes use
Covered
The CRS says Ozempic is approved for type 2 diabetes, a covered indication.
Source trail: Congressional Research Service
Weight loss
Excluded
The CRS says Part D excludes GLP-1 drugs used only for weight loss.
Source trail: Congressional Research Service
The Bridge
Not included
CMS says the Bridge covers certain weight-management drugs, which does not include Ozempic.
Source trail: CMS
Price negotiation
Effective 2027
CMS says Ozempic was selected for Medicare drug price negotiation.
Source trail: CMS
The key is the diagnosis: Ozempic is a diabetes drug to Medicare, so its coverage follows the diabetes indication, not weight loss.
Neutral landscape
The shape of the question
The Congressional Research Service is the main source because it identifies Ozempic as a type 2 diabetes drug, a covered indication.
Source trail: Congressional Research Service
The weight-loss boundary matters, and the CRS says Part D excludes GLP-1 drugs used only for weight loss.
Source trail: Congressional Research Service
The Bridge does not apply, since the CMS form covers weight-management drugs rather than Ozempic.
Source trail: CMS
Cost is changing, because CMS selected Ozempic for negotiation with prices effective in 2027.
Source trail: CMS
Curator core
What the authorities say
These sources are here for the reader who wants to check the work. The plain-English answer stays above them.
Source 01
Congressional Research Service
Medicare Coverage of GLP-1 Drugs
The Congressional Research Service summarizes Medicare coverage of GLP-1 drugs, including the statutory weight-loss exclusion and coverage for diabetes and cardiovascular indications.
Source framing
The Congressional Research Service says GLP-1 drugs are not covered under Part D when used for weight loss, but are covered for medically accepted indications such as type 2 diabetes and cardiovascular risk reduction.
Strongest for: the weight-loss exclusion and the covered medical indications
Read at Congressional Research ServiceSource 02
CMS
Medicare GLP-1 Bridge Prior Authorization Form
The CMS Bridge prior authorization form lists the Part D-eligible diagnoses that route to a Part D plan and the body-mass-index and lifestyle conditions for the Bridge.
Source framing
CMS says diagnoses like type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea, and MASH route to the Part D plan, while the Bridge covers weight management with body-mass-index and lifestyle conditions.
Strongest for: which diagnoses go to Part D versus the Bridge, and the Bridge conditions
Read at CMSSource 03
CMS
Medicare Drug Price Negotiation Selections
CMS announced the second cycle of Medicare drug price negotiations, which selected Ozempic, Rybelsus, and Wegovy, with negotiated prices effective in 2027.
Source framing
CMS says Ozempic, Rybelsus, and Wegovy were selected for Medicare drug price negotiation, with negotiated prices effective in 2027, and that Part D out-of-pocket spending is capped at $2,000 a year.
Strongest for: GLP-1 drug price negotiation and the Part D out-of-pocket cap
Read at CMSPlain-English forks
The forks people face
Most retirement questions hide a few smaller decisions. These are the practical pieces that change the plan.
Is the prescription for diabetes?
Why it matters: Ozempic is a diabetes drug, so a diabetes diagnosis is the covered path.
In real life: This fork is the covered indication.
What to look at: What to look at: the CRS summary of approved uses.
Are you seeking it for weight loss?
Why it matters: The CRS says weight loss alone is excluded from Part D.
In real life: This fork points to a different pathway or drug.
What to look at: What to look at: the weight-loss exclusion and the Bridge brands.
Are you planning for 2027 prices?
Why it matters: CMS selected Ozempic for negotiation, effective 2027.
In real life: This fork affects future cost.
What to look at: What to look at: the CMS negotiation announcement.
Common questions
Quick answers
Short, plain answers for the questions people usually have next. The source trail stays available below.
Does Medicare cover Ozempic for diabetes?+
The Congressional Research Service says Ozempic is approved for type 2 diabetes, a medically accepted indication, so Part D covers it for that use.
Does Medicare cover Ozempic for weight loss?+
The CRS says Part D does not cover GLP-1 drugs, including Ozempic, when used for weight loss.
Is Ozempic part of the GLP-1 Bridge?+
No. The CMS Bridge form covers certain weight-management drugs, which does not include Ozempic.
What about Rybelsus?+
Rybelsus is an oral form of semaglutide approved for type 2 diabetes, so Part D covers it for that indication, like Ozempic.
Will Ozempic get cheaper under Medicare?+
CMS says Ozempic was selected for Medicare drug price negotiation, with negotiated prices effective in 2027.
How this page is curated
This page uses the Congressional Research Service summary, the CMS GLP-1 Bridge form, and the CMS drug-price-negotiation announcement. It centers the diabetes indication because that is what drives Ozempic coverage.
Read the planner methodologyTrust anchor
Sources used on this page
Every source named above is listed here in one place.
CMS. Medicare GLP-1 Bridge Prior Authorization Form
https://www.cms.gov/glp-1-bridge.pdfCMS. Medicare Drug Price Negotiation Selections
https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lowerCongressional Research Service. Medicare Coverage of GLP-1 Drugs
https://www.congress.gov/crs-product/IF12758
Before you act on this
This plan is educational. It is not personalized financial, tax, or insurance advice. Projections illustrate the math, they do not predict the future. Talk to your own licensed financial professional before acting on any of it.